StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
28
Publishing Date
2023 - 11 - 14
1
2023 - 09 - 05
1
2023 - 08 - 09
1
2023 - 03 - 08
1
2022 - 10 - 17
1
2022 - 08 - 27
1
2022 - 08 - 17
1
2022 - 06 - 07
1
2022 - 05 - 05
1
2022 - 02 - 28
1
2022 - 02 - 18
2
2021 - 12 - 05
1
2021 - 11 - 15
2
2021 - 10 - 02
1
2021 - 09 - 28
2
2021 - 09 - 22
1
2021 - 08 - 31
2
2021 - 08 - 23
1
2021 - 08 - 09
1
2021 - 07 - 28
1
2021 - 06 - 07
1
2021 - 05 - 24
1
2021 - 05 - 17
1
2021 - 04 - 16
1
Sector
Health technology
28
N/a
2
Tags
Agreement
50
Alliances
52
Antibody
45
Approval
95
Biopharma
184
Biotech-beach
46
Biotechnology
121
Cancer
139
Care
64
Ceo
59
Clinical-trials-phase-ii
54
Clinical-trials-phase-iii
52
Collaboration
59
Commercialization
50
Companies
43
Conference
64
Covid
298
Covid-19
227
Device
76
Disease
108
Drug
225
Earnings
52
Europe
51
Events
49
Expected
59
Fda
229
Fda-approvals
61
Financial
74
Global
423
Growing
64
Growth
302
Health
98
Layoffs
83
License
45
Market
764
Medical
64
Merge
54
Money
94
N/a
2896
News
172
People
229
Pharm-country
71
Pharma
105
Pharmaceutical
99
Positive
46
Product-news
58
Reach
64
Regulatory
58
Report
345
Research
318
Results
220
Sales
53
Study
68
Technology
45
Therapeutics
189
Therapy
103
Treatment
198
Trial
99
Vaccine
327
Year
55
Entities
Addex therapeutics ltd
8
Advaxis, inc.
9
Adverum biotechnologies, inc.
8
Aldeyra therapeutics, inc.
9
Algernon pharmaceuticals inc.
19
Alnylam pharmaceuticals, inc.
11
Alterity therapeutics limited
25
Altimmune, inc.
12
Amgen inc.
15
Anavex life sciences corp.
11
Arrowhead pharmaceuticals, inc.
17
Athira pharma, inc.
10
Atossa therapeutics, inc.
11
Ayala pharmaceuticals, inc.
14
Beigene, ltd.
8
Biogen inc.
13
Biophytis - adr
8
Biorestorative therapies, inc.
10
Biovie inc.
8
Bridgebio pharma, inc.
11
Bristol-myers squibb company
15
Clene inc
15
Cognition therapeutics inc
8
Curevac n.v.
11
Denali therapeutics inc.
8
Dynavax technologies corporation
12
Eli lilly and company
34
Eloxx pharmaceuticals, inc.
11
Entera bio ltd.
8
Evelo biosciences, inc.
9
First wave biopharma, inc.
13
G1 therapeutics, inc.
9
Galecto, inc.
8
Gilead sciences, inc.
9
Hepion pharmaceuticals, inc.
10
I-mab
26
Ideaya biosciences, inc.
13
Immunic, inc.
11
Immunitybio inc
11
Incyte corporation
19
Johnson & johnson
28
Kintara therapeutics, inc.
8
Lipocine inc.
8
Longeveron llc - class a
13
Mediwound ltd.
13
Metacrine, inc.
10
Moderna, inc.
13
Mymd pharmaceuticals inc
8
Ocuphire pharma inc.
12
Orange
8
Pds biotechnology corporation
15
Pfizer, inc.
12
Protagonist therapeutics, inc.
10
Redhill biopharma ltd.
16
Sanofi
43
Scholar rock holding corporation
8
Sorrento therapeutics, inc.
20
Springworks therapeutics, inc.
9
Todos medical ltd.
8
Vir biotechnology, inc.
10
Symbols
ADXN
3
ARCT
2
ARWR
2
EVOTF
2
GMAB
1
GNMSF
1
INVVY
2
JNJ
28
SNY
2
SNYNF
1
TAK
2
Exchanges
Nasdaq
13
Nyse
28
Crawled Date
2023 - 11 - 14
1
2023 - 09 - 05
1
2023 - 08 - 09
1
2023 - 03 - 08
1
2022 - 10 - 17
1
2022 - 08 - 28
1
2022 - 08 - 17
1
2022 - 06 - 07
1
2022 - 05 - 05
1
2022 - 02 - 28
1
2022 - 02 - 18
2
2021 - 12 - 05
1
2021 - 11 - 15
2
2021 - 10 - 03
1
2021 - 09 - 28
2
2021 - 09 - 22
1
2021 - 08 - 31
2
2021 - 08 - 23
1
2021 - 08 - 09
1
2021 - 07 - 28
1
2021 - 06 - 07
1
2021 - 05 - 24
1
2021 - 05 - 17
1
2021 - 04 - 16
1
Crawled Time
00:20
2
05:00
1
06:00
4
07:00
3
09:00
2
11:00
1
12:00
2
12:15
2
13:00
1
13:20
1
14:00
2
15:00
2
15:30
1
17:00
1
19:00
1
20:00
1
20:20
1
Source
www.biospace.com
12
www.globenewswire.com
10
www.prnewswire.com
6
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Phase 2
entities :
Johnson & johnson
save search
Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients
Published:
2023-11-14
(Crawled : 06:00)
- globenewswire.com
JNJ
|
News
|
$148.53
-0.69%
0.18%
7.5M
|
Health Technology
|
0.49%
|
O:
0.17%
H:
0.0%
C:
0.0%
adx7114
study
phase 2
Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024
Published:
2023-09-05
(Crawled : 05:00)
- globenewswire.com
JNJ
|
News
|
$148.53
-0.69%
0.18%
7.5M
|
Health Technology
|
-8.27%
|
O:
-0.58%
H:
0.0%
C:
0.0%
ADXN
|
$15.55
-17.02%
-10.32%
12K
|
Health Technology
|
71.26%
|
O:
10.13%
H:
6.8%
C:
6.06%
adx7114
expected
readout
study
phase 2
PAN-TB Collaboration Announces the Start of a Phase 2 Clinical Trial to Evaluate Two Novel Tuberculosis Treatment Regimens
Published:
2023-08-09
(Crawled : 17:00)
- biospace.com/
JNJ
|
News
|
$148.53
-0.69%
0.18%
7.5M
|
Health Technology
|
-14.36%
|
O:
-0.16%
H:
0.0%
C:
0.0%
start
treatment
collaboration
trial
phase 2
ONL Therapeutics Closes First Tranche of $15 Million Series C Financing to Advance Lead Compound into Phase 2 Clinical Trial
Published:
2023-03-08
(Crawled : 14:00)
- biospace.com/
JNJ
|
News
|
$148.53
-0.69%
0.18%
7.5M
|
Health Technology
|
-3.86%
|
O:
-0.07%
H:
0.14%
C:
-0.66%
trial
therapeutics
phase 2
Bavarian Nordic’s COVID-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial
Published:
2022-10-17
(Crawled : 07:00)
- globenewswire.com
JNJ
|
News
|
$148.53
-0.69%
0.18%
7.5M
|
Health Technology
|
-9.81%
|
O:
0.63%
H:
0.0%
C:
0.0%
covid-19
candidate
antibody
vaccine
six
trial
response
phase 2
Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma
Published:
2022-08-27
(Crawled : 00:20)
- prnewswire.com
GMAB
|
News
|
$28.47
-0.32%
-0.32%
430K
|
Health Technology
|
Email alert
Add to watchlist
JNJ
|
News
|
$148.53
-0.69%
0.18%
7.5M
|
Health Technology
|
Email alert
Add to watchlist
GNMSF
|
News
|
$290.34
0.23%
3.83%
1.2K
|
Health Technology
|
Email alert
Add to watchlist
darzalex
study
phase 2
PAN-TB Collaboration to Advance Investigational Tuberculosis Drug Regimens to Phase 2 Clinical Trials
Published:
2022-08-17
(Crawled : 13:20)
- biospace.com/
JNJ
|
News
|
$148.53
-0.69%
0.18%
7.5M
|
Health Technology
|
-10.74%
|
O:
0.4%
H:
0.0%
C:
0.0%
trials
drug
collaboration
phase 2
Janssen Presents Initial Results from the Phase 2 RAGNAR Study of BALVERSA® (erdafitinib) in Patients with Advanced Solid Tumors with FGFR Alterations
Published:
2022-06-07
(Crawled : 15:00)
- prnewswire.com
JNJ
|
News
|
$148.53
-0.69%
0.18%
7.5M
|
Health Technology
|
-16.42%
|
O:
-0.18%
H:
0.0%
C:
0.0%
balversa
results
phase 2
Bavarian Nordic Reports Omicron Data from Phase 2 Trial of its COVID-19 Booster Vaccine Candidate
Published:
2022-05-05
(Crawled : 09:00)
- globenewswire.com
JNJ
|
News
|
$148.53
-0.69%
0.18%
7.5M
|
Health Technology
|
-16.86%
|
O:
0.72%
H:
0.0%
C:
0.0%
covid-19
vaccine
trial
phase 2
Bavarian Nordic Reports Additional Positive Phase 2 Results for its COVID-19 Vaccine Candidate Ahead of Phase 3 Trial
Published:
2022-02-28
(Crawled : 07:00)
- globenewswire.com
JNJ
|
News
|
$148.53
-0.69%
0.18%
7.5M
|
Health Technology
|
-7.4%
|
O:
1.79%
H:
0.0%
C:
0.0%
covid-19
phase 2
trial
covid
report
positive
phase 2 results
results
vaccine
phase 3
The Majority of Adults with Moderately to Severely Active Crohn's Disease in a Phase 2 Study Achieved Clinical Remission and Corticosteroid-Free Remission Through 48 Weeks with TREMFYA® (guselkumab)
Published:
2022-02-18
(Crawled : 20:00)
- biospace.com/
JNJ
|
News
|
$148.53
-0.69%
0.18%
7.5M
|
Health Technology
|
-10.86%
|
O:
-0.73%
H:
0.23%
C:
-0.98%
tremfya
phase 2
disease
active
New Phase 2b Data Show the Majority of Adults with Moderately to Severely Active Ulcerative Colitis Achieved Clinical Response with TREMFYA® (guselkumab) at 12 Weeks
Published:
2022-02-18
(Crawled : 15:30)
- prnewswire.com
JNJ
|
News
|
$148.53
-0.69%
0.18%
7.5M
|
Health Technology
|
-10.86%
|
O:
-0.73%
H:
0.23%
C:
-0.98%
tremfya
phase 2
phase 2b
response
active
pons
ulcerative colitis
Bavarian Nordic Reports Positive Topline Phase 2 Results for its COVID-19 Vaccine Candidate
Published:
2021-12-05
(Crawled : 20:20)
- globenewswire.com
JNJ
|
News
|
$148.53
-0.69%
0.18%
7.5M
|
Health Technology
|
Email alert
Add to watchlist
phase 2
covid
positive
phase 2 results
results
topline
vaccine
covid-19
Arrowhead Collaborator Presents Phase 2b Clinical Data from REEF-1 Study in Patients with Chronic Hepatitis B Infection
Published:
2021-11-15
(Crawled : 19:00)
- biospace.com/
JNJ
|
News
|
$148.53
-0.69%
0.18%
7.5M
|
Health Technology
|
-11.43%
|
O:
-1.36%
H:
0.0%
C:
0.0%
ARWR
|
$23.29
-2.06%
-2.13%
810K
|
Health Technology
|
-69.31%
|
O:
-3.29%
H:
0.86%
C:
-10.19%
phase 2
hepatitis
phase 2b
injection
infections
chronic hepatitis b
Addex Strategic Partner Successfully Completes Phase 1 in Japan with ADX71149
Published:
2021-11-15
(Crawled : 09:00)
- biospace.com/
JNJ
|
News
|
$148.53
-0.69%
0.18%
7.5M
|
Health Technology
|
-11.43%
|
O:
-1.36%
H:
0.0%
C:
0.0%
ADXN
|
$15.55
-17.02%
-10.32%
12K
|
Health Technology
|
-89.94%
|
O:
2.85%
H:
1.14%
C:
1.14%
phase 1
phase 2
xin
phase 3
Janssen Announces Phase 2b Data Demonstrating its Investigational RSV Adult Vaccine Provided 80% Protection Against Lower Respiratory Infections in Older Adults
Published:
2021-10-02
(Crawled : 00:20)
- prnewswire.com
JNJ
|
News
|
$148.53
-0.69%
0.18%
7.5M
|
Health Technology
|
Email alert
Add to watchlist
phase 2
respiratory
vaccine
phase 2b
injection
order
infections
Arrowhead Earns $10 Million Phase 1 Milestone Payment
Published:
2021-09-28
(Crawled : 12:15)
- biospace.com/
JNJ
|
News
|
$148.53
-0.69%
0.18%
7.5M
|
Health Technology
|
-9.21%
|
O:
-0.04%
H:
0.5%
C:
-0.18%
ARWR
|
$23.29
-2.06%
-2.13%
810K
|
Health Technology
|
-64.48%
|
O:
-0.99%
H:
0.0%
C:
-6.56%
phase 1
phase 2
phase 3
milestone
Sanofi announces positive Phase 1/2 study interim results for its first mRNA-based vaccine candidate
Published:
2021-09-28
(Crawled : 07:00)
- globenewswire.com
JNJ
|
News
|
$148.53
-0.69%
0.18%
7.5M
|
Health Technology
|
-9.21%
|
O:
-0.04%
H:
0.5%
C:
-0.18%
SNY
|
News
|
$46.61
-2.27%
-2.21%
1.6M
|
Health Technology
|
-1.4%
|
O:
0.15%
H:
0.06%
C:
-0.6%
phase 1
positive
results
vaccine
phase 2
phase 3
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
Published:
2021-09-22
(Crawled : 12:00)
- biospace.com/
TAK
|
News
|
$13.23
-1.12%
0.0%
920K
|
Health Technology
|
-23.17%
|
O:
-0.17%
H:
0.0%
C:
-1.11%
JNJ
|
News
|
$148.53
-0.69%
0.18%
7.5M
|
Health Technology
|
-9.96%
|
O:
0.5%
H:
0.36%
C:
-0.86%
ARCT
4
|
$26.98
-3.4%
-3.44%
270K
|
Health Technology
|
-47.93%
|
O:
1.81%
H:
2.1%
C:
-0.32%
phase 2
vaccine
phase 3
approval
sars-cov-2
Johnson & Johnson and Global Partners Announce Results from Phase 2b Imbokodo HIV Vaccine Clinical Trial in Young Women in Sub-Saharan Africa
Published:
2021-08-31
(Crawled : 12:00)
- biospace.com/
JNJ
|
News
|
$148.53
-0.69%
0.18%
7.5M
|
Health Technology
|
-14.7%
|
O:
-0.1%
H:
0.58%
C:
-0.21%
phase 2
women
results
vaccine
phase 2b
trial
hiv
africa
← Previous
1
2
Next →
Gainers vs Losers
62%
38%
Top 10 Gainers
CSSE
4
|
$0.4253
179.25%
64.77%
210M
|
Consumer Services
BOF
|
$2.08
77.78%
41.21%
110M
|
ILAG
|
$0.54
12.27%
40.62%
3.7M
|
LICN
|
$0.999
78.39%
40.49%
15M
|
AMST
|
$3.4
70.0%
39.58%
70M
|
Technology Services
MTC
|
$3.6
60.71%
38.04%
9.1M
|
Technology Services
WIMI
|
$1.15
58.53%
36.92%
19M
|
Technology Services
AIH
|
$0.458
14.5%
30.92%
91K
|
Health Services
WHLM
|
$6.25
35.87%
28.46%
700K
|
Commercial Services
MULN
|
News
|
$3.77
38.1%
27.78%
13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.